Article

ACE2 Can Act as the Secondary Receptor in the FcγR-Dependent ADE of SARS-CoV-2

2021-08-23

Abstract excerpt

Currently, it is not clear whether antibody-mediated enhancement (ADE) is involved in the pathogenesis of COVID-19, and the occurrence condition for ADE needs to be elucidated. We demonstrated that different from the reported RBD-targeting neutralizing antibody XG005 which elicits an ACE2-independent ADE on Raji cells, neutralizing antibody CB6, mouse anti-S1 serum and convalescent plasma could not elicit ADE on R...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c08820a1-31a9-5ccf-90a4-fd750094189c
DOI: 10.2139/ssrn.3910133

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ACE2 Can Act as the Secondary Receptor in the FcγR-Dependent ADE of SARS-CoV-2DOI 10.2139/ssrn.3910133Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBDSemantic proximity Read

SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infectionSemantic proximity Read

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodySemantic proximity Read

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2Semantic proximity Read

ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for <i>in vivo</i> efficacy against SARS-CoV-2Semantic proximity Read

An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodiesSemantic proximity Read

Structural Insights Into the Design of Peptide-based Drug or Diagnostic Reagent Antagonizing SARS-COV-2Semantic proximity Read

Antibody-dependent enhancement of coronavirusesSemantic proximity Read

S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basisSemantic proximity Read